Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock Analysis & Winston Score

Acrivon Therapeutics is a small biotech company focused on developing cancer treatments. Its main approach centers on a drug called ACR-368, which targets certain proteins that help cancer cells survive and divide. The company uses its own technology platform, called Acrivon Proteomics, to identify which patients are most likely to respond to its drugs before they even start treatment. Acrivon does not yet sell any approved products, so it earns no revenue from sales. It is funded primarily through cash raised from investors, which it uses to run clinical trials. The company operates mainly in the United States and had a market cap of roughly $100 million as of mid-2026, making it a very small player in the biotech space. Its key competitive idea is matching the right drug to the right patient using its proteomics platform, but the biggest risk is that its lead drug could fail in clinical trials, which would put the company's future in serious doubt.